Compositions employing alternative reading frame polypeptides for the treatment of cancer and infectious disease

A fusion protein comprising,

• two or more alternative reading frame (ARF) polypeptides wherein each of said ARF polypeptides comprises at least 9 amino acids of an ARF polypeptide derived from a polynucleotide selected from the group consisting of human tyrosine kinase receptor (hHER-2, SEQ ID NO:
• 2);
• human telomerase reverse transcriptase (hTERT, SEQ ID NO:
• 4);
• mouse telomerase reverse transcriptase (mTERT, SEQ ID NO:
• 6);
• human transient receptor potential cation channel 8 (hTrpP8, SEQ ID NO:
• 8);
• human prostatic acid phosphatase (hPAP, SEQ ID NOs:
• 10);
• human prostatic acid phosphatase (hPAP, SEQ ID NOs:
• 12);
• human carbonic anhydrase IX (hCA9, SEQ ID NO:
• 295);
• human carcinoembryonic antigen (hCEA, SEQ ID NO:
• 302);
• human prostate-specific membrane antigen (hPSMA;
• SEQ ID NO:
• 345), human prostate-specific antigen (hPSA, SEQ ID NO:
• 369);
• human p53 cellular tumor antigen (hp53;
• SEQ ID NO:
• 381);
• human P-glycoprotein (hPGY1;
• SEQ ID NO:
• 392);
• human alpha-fetoprotein (hAFP;
• SEQ ID NO:
• 424);
• human mucin precursor (hMUC1;
• SEQ ID NO:
• 441);
• human preferentially expressed antigen of melanoma (hPRAME;
• SEQ ID NO:
• 452);
• human ephrin receptor (hEPHA3;
• SEQ ID NO:
• 468);
• human peptidyl-prolyl isomerase and essential mitotic regulator (hPIN1;
• SEQ ID NO:
• 496);
• human BASE (hBASE;
• SEQ ID NO:
• 504);
• human prostate stem cell antigen (hPSCA;
• SEQ ID NO:
• 515);
• human SURVIVIN (hSURVIVIN;
• SEQ ID NO:
• 549);
• human WTI (hWTI;
• SEQ ID NO:
• 557);
• human SGA-M1 (hSGA-M1;
• SEQ ID NO:
• 566);
• human RCAS1 (hRCAS1;
• SEQ ID NO:
• 579);
• and human CYP1B1 (hCYP1B1;
• SEQ ID NO:
• 592) or a complement of any of the foregoing polynucleotides,
• wherein the ARF polypeptide corresponds to a polypeptide generated by an in vivo translational error resulting in frame-shifting of the initiation complex at a normal rf0 AUG codon one base (rf1) or two bases (rf2) forward or one base (rf2) or two bases (rf1) backward.